Molecular Partners at PEGS Europe 2026

Nov 16–19, 2026 Lisbon, Portugal ~1.5k attendees Website

Molecular Partners brings 3 presentations to PEGS Europe 2026 in Lisbon. Its program centres on DARPin cancer therapeutics, including an AND-gated switch DARPin T cell engager with CD2 co-stimulation for ovarian cancer. It also covers first-in-human data for a DARPin in targeted alpha therapy and the radio-DARPin candidates behind it.

OrganizationPEGS Europe 2026 Attendance
Molecular Partners
Zurich, Switzerland
molecularpartners.com
Biotech
Clinical-stage developer of DARPin therapeutics, including T cell engagers and radio-DARPins for cancer.
Chair
Tue Nov 17
2:00pm–2:05pm
Chairperson's Remarks
T Cell Engagers · with Vir Biotechnology
Talk
Tue Nov 17
2:35pm–3:05pm
Talk
Tue Nov 17
5:20pm–5:50pm

Explore the full PEGS Europe 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in Lisbon. Leave your work email and we’ll be in touch.

Privacy

Download the full PEGS Europe 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Instantly find 20 buyers from Molecular Partners

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by PEGS Europe or its organizers. Submit a correction